Scleroderma renal crisis
SRC · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Acute, often malignant hypertension with rapidly progressive AKI and thrombotic microangiopathy in systemic sclerosis, typically early diffuse disease. Prompt ACE inhibitor therapy is life- and kidney-saving and is the cornerstone of treatment.
Red flags
- Rapidly rising creatinine with severe hypertension
- Microangiopathic haemolytic anaemia with thrombocytopenia
- Hypertensive encephalopathy or pulmonary oedema
- Recent high-dose corticosteroid exposure
- Normotensive renal crisis (worse prognosis)
Assessment
Differential diagnosis
- Scleroderma renal crisis
- Malignant hypertension from another cause
- Thrombotic microangiopathy (TTP/aHUS)
- ANCA-associated vasculitis (can overlap in scleroderma)
- Acute glomerulonephritis
- Drug-induced (high-dose corticosteroid-precipitated)
Investigations
- Blood pressure (often markedly elevated; occasionally normotensive crisis)
- U&E/creatinine trend, FBC (thrombocytopenia), blood film (schistocytes), LDH, haptoglobin
- Urinalysis (mild proteinuria, few casts)
- Renin (markedly elevated)
- ANA/anti-RNA polymerase III, ANCA and anti-GBM (exclude overlap)
- Renal biopsy only if diagnosis unclear (onion-skin vessels, TMA)
Management
- Recognise the triad: new accelerated hypertension, rapidly rising creatinine and microangiopathic haemolysis in systemic sclerosis (especially early diffuse disease on steroids)
- Start an ACE inhibitor immediately and titrate rapidly to control BP — do this even if renal function transiently worsens
- Aim to lower BP steadily (e.g. by ~20 mmHg/day toward target) rather than precipitously
- Add additional antihypertensives (calcium-channel blocker, others) if ACE inhibitor alone is insufficient — but never stop the ACE inhibitor
- Avoid high-dose corticosteroids, which precipitate renal crisis
- Support renal failure: manage fluid, electrolytes and start dialysis if needed (many recover function over months)
- Distinguish from and exclude overlapping TTP/aHUS and vasculitis if the picture is atypical
- Monitor haemolysis markers and platelet recovery
- Continue the ACE inhibitor long-term even if dialysis is required — renal recovery can occur up to 1-2 years later
- Manage as inpatient/HDU with close BP and renal monitoring
- Treat the underlying systemic sclerosis with rheumatology input (avoiding steroids where possible)
- Provide long-term nephrology and rheumatology follow-up
Drugs & doses
Captopril 6.25-12.5 mg PO, uptitrated rapidly every few hours to control BP (short-acting ACE inhibitor preferred for titration)
Enalapril/ramipril once converted from captopril for maintenance
Amlodipine 5-10 mg PO daily or other agent added if BP not controlled on ACE inhibitor
Labetalol/IV antihypertensive as adjunct in severe cases (never replacing ACE inhibitor)
Disposition
Admit (HDU/ICU) under nephrology with rheumatology; rapid ACE inhibitor titration. Dialysis as needed with long-term ACE inhibitor continuation and specialist follow-up.
Complications & pitfalls
- Irreversible renal failure requiring dialysis
- Hypertensive encephalopathy, heart failure
- Microangiopathic haemolysis
- Pericardial effusion/tamponade
- Death if untreated
Exam pearls
- ACE inhibitors are life-saving and must be continued even as creatinine rises or on dialysis
- High-dose steroids precipitate scleroderma renal crisis — avoid them in at-risk scleroderma
- Anti-RNA polymerase III antibody and early diffuse disease mark high risk
- Renal recovery can occur months later — do not abandon the ACE inhibitor
- A normotensive crisis exists and carries a worse prognosis
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.